Bangalore, Karnataka -- (SBWIRE) -- 04/20/2017 -- According to Orphan Drug Designation program of the US Food and Drug Administration (FDA), orphan diseases are defined as rare diseases that affects less than 2,00,000 Americans. The global orphan drugs market is expected to benefit from patent extensions like Orphan Drug Exclusivity (ODE), increasing focus of vendors on orphan drug products, and financial incentives provided by government in form of tax credits and waived FDA fees. For instance, the FDA grants a seven-year patent exclusivity to orphan drugs to treat a rare disease. Therefore, any other drug with the same indication cannot be approved by the FDA during these seven-years period. In addition, they also provide tax credits up to 50% of the total R&D cost after the drug receives the orphan drug designation. This credit can be used by the sponsor during the R&D phase of any drug irrespective of the drug designation. The orphan designated drugs are also exempted from paying the FDA fees. Thus, these financial incentives and grants for orphan drug attract many vendors to invest in developing drugs for rare diseases and make huge profits.

Report forecast the global orphan drugs market to grow at a CAGR of 10.20% during the period 2017-2021.

The report covers the present scenario and the growth prospects of the global orphan drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Global Orphan Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- AbbVie
- Celgene
- F. Hoffmann La Roche
- Novartis

Other prominent vendors
- Amgen
- Actelion
- Alexion Pharmaceuticals
- Bayer
- Biogen
- Bristol-Myers Squibb
- Eli Lilly
- Johnson & Johnson
- Novo Nordisk
- Pfizer
- Sanofi
- Shire
- Teva pharmaceutical

Market driver
- Large growth opportunities through orphan drug designation.
- For a full, detailed list, view our report

Market challenge
- Costly treatment regimen results in financial burden on patients.
- For a full, detailed list, view our report

Market trend
- Emerging application for orphan drug development.
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Spanning over 70 pages "Global Orphan Drugs Market 2017-2021" report covers Executive summary, Scope of the report, Research Methodology, Introduction, Market landscape, Regulatory approval, Market segmentation by product type, Geographical segmentation, Decision framework, Drivers and challenges, Market trends, Competitive Scenario, Key vendor analysis, Appendix.

For more information Visit at: http://www.drugpipeline.net/technavio/global-orphan-drugs-market-2017-2021

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.